Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Growth Rate of the Hypercalcemia Treatment Market?
The market size for hypercalcemia treatment has seen swift expansion in the past few years. The sector is projected to evolve from a value of $16.44 billion in 2024 to $18.34 billion in 2025, with a compound annual growth rate (CAGR) of 11.5%. The noticeable progress during the historic period can be credited to factors such as the growing knowledge about hypercalcemia, the increase in the elderly population, the increasing number of cancer cases, enhanced disease understanding, and a surge in parathyroid-related disorders occurrences.
What Growth Rate Is Forecasted for the Hypercalcemia Treatment Market by 2029?
The market for hypercalcemia treatment is predicted to witness swift expansion over the upcoming years. Its growth will reach an astonishing $28.31 billion by 2029, having a compound annual growth rate (CAGR) of 11.5%. The growth anticipated during this forecast period stems from the increasing incidence of chronic kidney disease, higher numbers of hypertension patients, a surge in funding for the development of new medicinal approaches, heightened awareness as well as patient empowerment, and governmental endeavors. Notable trend forecasts for this period include enhanced diagnostic methods and procedures, progress in treatment options, new treatment drugs being introduced, and partnerships among healthcare providers.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21206&type=smp
Which Key Companies Are Shaping the Future of the Hypercalcemia Treatment Market?
Major companies operating in the hypercalcemia treatment market are Pfizer Inc., Roche Holding AG, AbbVie Inc., AstraZeneca plc, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Merck KGaA, Fresenius Medical Care AG & Co. KGaA, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Ipsen SA, Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals plc, Endo International plc, OPKO Health Inc., Ferring Pharmaceuticals A/S, Rockwell Medical Inc., Strides Pharma Science Limited
Which Factors Are Driving Demand in the Hypercalcemia Treatment Industry?
The increasing incidence of parathyroid disorders is anticipated to stimulate the expansion of the hypercalcemia treatment market in the future. Parathyroid disorders pertain to those illnesses that impact the parathyroid glands, responsible for regulating calcium amounts within the body via the creation of parathyroid hormone (PTH). Factors facilitating the spike in parathyroid disorder prevalence include an aging demographic, heightened awareness, improved diagnosis skills, and the escalating occurrence of conditions like primary hyperparathyroidism and chronic kidney disease. Hypercalcemia treatment is vital in managing these disorders by controlling escalated calcium levels, staving off conditions such as kidney stones and bone loss, and enhancing overall metabolic equilibrium. For instance, the National Institute of Health (NIH), a government agency based in the US, revealed in February 2024 that hypoparathyroidism is projected to impact 6.4 to 37 out of every 100,000 people per year, with 75% of instances being the result of complications related to thyroidectomy or head and neck surgeries. Consequently, the upsurge in parathyroid disorder prevalence is propelling the growth of the hypercalcemia treatment market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21206&type=smp
How Is the Hypercalcemia Treatment Market Segmented by Several Divisions?
The hypercalcemia treatment market covered in this report is segmented –
1) By Drug Type: Bisphosphonates, Calcitonin, Glucocorticoids, Denosumab, Calcimimetics, Other Drug Types
2) By Indication: Primary Hyperthyroidism, Hypercalcemia Of Malignancy, Other Indications
3) By Distribution Channel: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End-Users: Hospitals, Clinics
Subsegments:
1) By Bisphosphonates: Zoledronic Acid, Pamidronate, Alendronate
2) By Calcitonin: Salmon Calcitonin, Synthetic Calcitonin
3) By Glucocorticoids: Prednisone, Dexamethasone, Hydrocortisone
4) By Denosumab: Denosumab (Monotherapy), Denosumab Combination Therapy
5) By Calcimimetics: Cinacalcet, Etelcalcetide
6) By Other Drug Types: Gallium Nitrate, Mithramycin
What are the Emerging Market Trends Driving the Growth of the Hypercalcemia Treatment Industry?
Leading entities within the hypercalcemia treatment market are giving priority to the creation of novel products like phosphate binders. These products provide a more efficient management of calcium and phosphorus equilibrium, thereby enhancing treatment results. Phosphate binders are drugs used to block the absorption of phosphate in the digestive system, making them a common solution for controlling high phosphate concentrations in individuals with kidney disease or hypercalcemia. To illustrate, Strides Pharma Science Limited, an Indian pharmaceutical enterprise, gained approval for its Sevelamer Carbonate Tablets, 800 mg from the United States Food and Drug Administration (FDA) in May 2024. These tablets effectively control hyperphosphatemia in patients suffering from chronic kidney disease by binding dietary phosphate and obstructing its absorption. Besides, these tablets contribute to maintaining bone wellbeing and lessen cardiovascular risks linked to high phosphate levels.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/hypercalcemia-treatment-global-market-report
Which Regions Are Driving Growth in the Hypercalcemia Treatment Market?
North America was the largest region in the hypercalcemia treatment market in 2024. The regions covered in the hypercalcemia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21206
This Report Delivers Insight On:
1. How big is the hypercalcemia treatment market, and how is it changing globally?
2. Who are the major companies in the hypercalcemia treatment market, and how are they performing?
3. What are the key opportunities and risks in the hypercalcemia treatment market right now?
4. Which products or customer segments are growing the most in the hypercalcemia treatment market?
5. What factors are helping or slowing down the growth of the hypercalcemia treatment market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model